Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurobiology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RND1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RND1 Recombinant Protein (WT/Mutant) High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for PPI assays. |
View RND1 Products |
| Gene Delivery | RND1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and cytoskeletal remodeling assays. |
View RND1 Products |
| Benchmark Ab | Anti-RND1 Recombinant Antibody High-affinity sequence-verified positive control for Western Blot and IHC. |
View RND1 Products |
| Validator | RND1 siRNA Set Target-specific knockdown verification in phenotypic assays. |
View RND1 Products |
| Related Target A | PLXNB1 (Plexin-B1) Primary functional binding partner; mediates RND1-dependent RhoA inhibition. |
View PLXNB1 Products |
| Related Target B | RHOA Downstream signaling node antagonized by RND1 activation. |
View RHOA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Target Accessibility | Lentiviral vectors optimized for high-efficiency transduction in primary and hard-to-transfect cell lines. |
| Constitutive GTP-bound State Mimicry | Recombinant RND1 proteins sequence-verified to retain native GTP-binding pocket structure. |
| Lack of Controls | Sequence-defined recombinant benchmark antibodies included for assay standardization. |
| False Positives in PPI Screens | Validated siRNA sets included for target-specific knockdown rescue experiments. |
Live RND1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of RND1, a constitutively active Rho family GTPase, is gaining momentum in oncology and regenerative medicine. As a key regulator of actin dynamics, cell adhesion, and neurite outgrowth, RND1 acts primarily as a tumor suppressor in several epithelial cancers, while its dysregulation is linked to aggressive metastatic phenotypes and glioblastoma progression.
The race for RND1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to small molecule protein-protein interaction (PPI) inhibitors and RNA-based therapeutics. As first-generation therapies reach the clinic, the next wave of R&D is targeting the RND1-Plexin-B1 signaling axis to modulate tumor invasion and promote neural regeneration.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic Medical Centers, Biotech Startups | Solid Tumors, Glioblastoma | In vitro binding assays requiring high-purity recombinant RND1 and PLXNB1 proteins. |
| Gene Therapy / mRNA | RNA Therapeutics Specialists | Neurodegenerative Diseases, Spinal Cord Injury | Lentiviral delivery systems to validate expression and downstream neurite outgrowth. |
| siRNA Therapeutics | Oligonucleotide Therapeutics Developers | Metastatic Cancers | Sequence-verified siRNA pools for high-throughput screening and target validation. |